Conference Coverage

Poor evidence for vaginal laser therapy


 

FROM NAMS 2022

Recommendations on vaginal laser therapy

Given this landscape of uneven and poor-quality evidence, Dr. Iglesia provided several “common sense” recommendations for energy-based therapies, starting with the need for any practitioner to have working knowledge of vulvovaginal anatomy. Contraindications for laser therapy include any malignancy – especially gynecologic – undiagnosed bleeding, active herpes or other infections, radiation, and vaginal mesh, particularly transvaginal mesh. The provider also must discuss the limited data on long-term function and treatment alternatives, including FDA-approved therapies like topical estrogen, dehydroepiandrosterone sulfate (DHEA-S), ospemifene, and moisturizers, Dr. Iglesia said.

Adverse events associated with laser therapy, such as scarring or burning, are rare but do occur, and cost remains an issue, Dr. Iglesia said.

“Vaginal estrogen therapy is well established as a safe and effective treatment option based on high quality evidence,” Dr. Christmas said. “This is not the case for laser therapy. Rare, but serious harms are reported with vaginal laser, including burns, scarring, dyspareunia, pain, and potential irreversible damage.”

Dr. Iglesia also cautioned that clinicians should take extra care with vulnerable populations, particularly cancer patients and others with contraindications for estrogen treatment.

For those in whom vaginal estrogen is contraindicated, Dr. Christmas recommended vaginal moisturizers, lubricants, dilators, and physical therapy for the pelvic floor.

“In patients who fail those nonhormonal approaches, short courses of vaginal estrogen therapy or DHEA-S suppository may be employed with approval from their oncologist,” Dr. Christmas said.

Dr. Iglesia finally reviewed the major research questions that remain with laser therapy:

  • What are outcomes for laser versus sham studies?
  • What are long-term outcomes (beyond 6 months)
  • What pretreatment is necessary?
  • Could laser be used as a drug delivery mechanism for estrogen, and could this provide a synergistic effect?
  • What is the optimal number and interval for laser treatments?

Dr. Iglesia had no industry disclosures but received honoraria for consulting at UpToDate. Dr. Christmas is a consultant for Materna. The presentation did not rely on any external funding.

Pages

Recommended Reading

2022 Update on menopause
MDedge ObGyn
Hormone therapy didn’t increase recurrence or mortality in women treated for breast cancer
MDedge ObGyn
Routine weight counseling urged for women at midlife
MDedge ObGyn
NAMS affirms value of hormone therapy for menopausal women
MDedge ObGyn
Does cannabis help with menopause symptoms?
MDedge ObGyn
How should you advise your 54-year-old patient about the use of HT?
MDedge ObGyn
Early menopause linked with increased risk of heart problems
MDedge ObGyn
New ovulatory disorder classifications from FIGO replace 50-year-old system
MDedge ObGyn
Early or delayed menopause and irregular periods tied to new-onset atrial fibrillation
MDedge ObGyn
Hormone changes: The star of every stage in women’s sleep
MDedge ObGyn